Literature DB >> 6336978

Prostatic cancer presenting as metastatic adenocarcinoma of undetermined origin. Immunodiagnosis by prostatic acid phosphatase.

L T Yam, C F Winkler, A J Janckila, C Y Li, K W Lam.   

Abstract

Adenocarcinoma of the prostate may occasionally present as distant metastatic disease. This tumor, if accurately identified, is amendable to effective treatment with hormonal manipulations. We have seen nine patients with prostatic cancer presenting as metastatic adenocarcinoma of undetermined origin: two presented with involvement in the lung and the mediastinum, five with left supraclavicular lymphadenopathy and two with known prostatic cancer with stable disease presented with supraclavicular lymphadenopathy. By employing an immunoperoxidase technique using prostatic acid phosphatase as the marker for the prostatic cells, we demonstrated the presence of the prostatic enzyme antigen in the paraffin embedded tissues from the metastatic tumor. This finding directed further investigation of the prostate gland leading to the discovery of the primary tumor in all nine patients. It may be beneficial to use this technique in all male patients with adenocarcinoma of undetermined primary site.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6336978     DOI: 10.1002/1097-0142(19830115)51:2<283::aid-cncr2820510220>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  A focused approach to patients with cancer of unknown primary site.

Authors:  F J Meyers; J P Lewis
Journal:  West J Med       Date:  1986-09

2.  Malignant Ascites Associated with Carcinoma of the Prostate.

Authors:  Muhammad Wasif Saif
Journal:  J Appl Res       Date:  2005-01-01

3.  Variation of prostate-specific antigen expression in different tumour growth patterns present in prostatectomy specimens.

Authors:  M P Gallee; E Visser-de Jong; J A van der Korput; T H van der Kwast; F J ten Kate; F H Schroeder; J Trapman
Journal:  Urol Res       Date:  1990
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.